Cost-effectiveness analysis of intranasal live attenuated vaccine (LAIV) versus injectable inactivated influenza vaccine (TIV) for Canadian children and adolescents

ClinicoEconomics and Outcomes Research

Volumn 4, Issue 1, 2012, Pages 287-298

  Tarride, Jean Eric ^a,b   Burke, Natasha ^a,b   Von Keyserlingk, Camilla ^a,b   O'Reilly, Daria ^a,b   Xie, Feng ^a,b   Goeree, Ron ^a,b  

^a PATH Research Institute   (Canada)

^b MCMASTER UNIVERSITY   (Canada)

Author keywords

Children; Cost effectiveness; Influenza; Vaccine

Indexed keywords

INFLUENZA VACCINE;

ABSENTEEISM; ADOLESCENT; AMBULATORY CARE; ARTICLE; CANADA; CHILD; COHORT ANALYSIS; CONTROLLED STUDY; COST EFFECTIVENESS ANALYSIS; DRUG APPROVAL; DRUG DOSAGE FORM COMPARISON; DRUG EFFICACY; EMERGENCY WARD; HEALTH CARE COST; HEALTH CARE UTILIZATION; HOSPITALIZATION; HUMAN; INFLUENZA; INFLUENZA VACCINATION; INJECTION SITE REACTION; LENGTH OF STAY; OUTCOME ASSESSMENT; OUTPATIENT DEPARTMENT; PARENT; PRESCHOOL CHILD; QUALITY ADJUSTED LIFE YEAR; RANDOMIZED CONTROLLED TRIAL (TOPIC); SCHOOL CHILD; WHEEZING;

EID: 84930486106     PISSN: None     EISSN: 11786981     Source Type: Journal    
DOI: 10.2147/CEOR.S33444     Document Type: Article

References (39)

1. Influenza [homepage on the Internet]. Ottawa: Public Health Agency of Canada; [updated February 12, 2012; cited June 27, 2010]. Available from: http://www.phac-aspc.gc.ca/influenza/index-eng.php. Accessed June 27, 2010.
2. American Academy of Pediatrics Committee on Infectious Diseases. Recommendations for influenza immunization of children. Pediatrics. 2004;113(5):1441-1447.
3. Glezen WP, Couch RB. Interpandemic influenza in the Houston area, 1974-1976. N Engl J Med. 1978;298(11):587-592.
4. Weycker D, Edelsberg J, Halloran ME, et al. Population-wide benefits of routine vaccination of children against influenza. Vaccine. 2005; 23(10):1284-1293.
5. Centers for Disease Control and Prevention. Estimates of Influenza Vaccination Target Population Sizes in 2006 and Recent Vaccine Uptake Levels. Atlanta, GA: Centers for Disease Control and Prevention; 2006. Available from: http://www.cdc.gov/flu/professionals/vaccination/pdf/targetpopchart.pdf. Accessed June 27, 2010.
6. Jackson LA, Neuzil KM, Baggs J, et al. Compliance with the recommendations for 2 doses of trivalent inactivated influenza vaccine in children less than 9 years of age receiving influenza vaccine for the first time: a Vaccine Safety Datalink study. Pediatrics. 2006;118(5): 2032-2037.
7. McIntosh K, Lieu T. Is it time to give influenza vaccine to healthy infants? N Engl J Med. 2000;342(4):275-276.
8. FLUMIST® (influenza vaccine, live, attenuated, intranasal spray) [product monograph]. Mississauga, ON: AstraZeneca Canada; 2010. Available at http://www.astrazeneca.ca/cs/Satellite?blobcol=urldata&blobheader=application%2Fpdf&blobheadername1=Content-Disposition&blobheadername2=MDT-Type&blobheadervalue1=inline%3B+filename%3DProduct-Monograph.pdf&blobheadervalue2=abinary%3B+charset%3DUTF-8&blobkey=id&blobtable=MungoBlobs&blobwhere=1285635966235&ssbinary=true.
9. National Advisory Committee on Immunization. Recommendations on the use of live, attenuated influenza vaccine (FluMist®): Supplemental statement on seasonal influenza vaccine for 2011-2012. Can Commun Dis Rep [serial on the Internet]. 2011 [cited March 26, 2012];37 [about 8 pp]. http://www.phac-aspc.gc.ca/publicat/ccdr-rmtc/11vol37/acs-dcc-7/recom-eng.php. Accessed March 26, 2012.
10. Luce BR, Nichol KL, Belshe RB, et al. Cost-effectiveness of live attenuated influenza vaccine versus inactivated influenza vaccine among children aged 24-59months in the United States. Vaccine. 2008;26(23): 2841-2848.
11. Statistics Canada.[Database on the Internet] Table 051-0001-Estimates of population, by age group and sex for July 1, Canada, provinces and territories, annual, CANSIM 2008. Available at: http://cansim2.statcan.gc.ca/cgi-win/cnsmcgi.pgm?Lang=E&ArrayId=510001&Array_Pick=1&RootDir=CII/&ResultTemplate=CII/CII.
12. Canadian Agency for Drugs and Technologies in Health (CADTH). Guidelines for the Economic Evaluation of Health Technologies: Canada. 3rd ed. Ottawa, ON: CADTH; 2006.
13. Belshe RB, Edwards KM, Vesikari T, et al; CAIV-T Comparative Efficacy Study Group. Live attenuated versus inactivated influenza vaccine in infants and young children. N Engl J Med. 2007;356(7): 685-696.
14. Belshe RB, Toback SL, Yi T, Ambrose CS. Efficacy of live attenuated influenza vaccine in children 6months to 17 years of age. Influenza Other Respi Viruses. 2010;4(3):141-145.
15. Rhorer J, Ambrose CS, Dickinson S, et al. Efficacy of live attenuated influenza vaccine in children: A meta-analysis of nine randomized clinical trials. Vaccine. 2009;27(7):1101-1110.
16. Prosser LA, Bridges CB, Uyeki TM, et al. Health benefits, risks, and cost-effectiveness of influenza vaccination of children. Emerg Infect Dis. 2006;12(10):1548-1558.
17. Mauskopf JA, Cates SC, Griffin AD, Neighbors DM, Lamb SC, Rutherford C. Cost effectiveness of zanamivir for the treatment of influenza in a high risk population in Australia. Pharmacoeconomics. 2000;17(6):611-620.
18. Revicki DA, Leidy NK, Brennan-Diemer F, Sorensen S, Togias A. Integrating patient preferences into health outcomes assessment: the multiattribute Asthma Symptom Utility Index. Chest. 1998;114(4): 998-1007.
19. Mittmann N, Trakas K, Risebrough N, Liu BA. Utility scores for chronic conditions in a community-dwelling population. Pharmacoeconomics. 1999;15(4):369-376.
20. Drummond MF, Sculpher MJ, Torrance GW, O'Brien BJ, Stoddard GL. Methods for the Economic Evaluation of Health Care Programmes. 3rd ed. Oxford: Oxford University Press; 2005.
21. Sebastian R, Skowronski DM, Chong M, Dhaliwal J, Brownstein JS. Age-related trends in the timeliness and prediction of medical visits, hospitalizations and deaths due to pneumonia and influenza, British Columbia, Canada, 1998-2004. Vaccine. 2008;26(10):1397-1403.
22. Statistics Canada. Women in Canada: A Gender-based Statistical Report, 1Fifth edition. Catalogue no. 89-503-XPE. ISBN 0-660-19504-6. Available at: http://publications.gc.ca/Collection-R/Statcan/89-503-X/0010589-503-XIE.pdf
23. Natural Resources Canada. The Atlas of Canada. Average distance to the nearest family physician, 1998. Available at: http://atlas.nrcan.gc.ca/site/english/maps/health/ruralhealth/distancephysicians/distancephysicianspecialist/1.
24. Canadian Automobile Association. Driving costs. http://www.caa.ca/documents/DrivingCostsBrochure-jan09-eng-v3.pdf
25. Sander B, Kwong JC, Bauch CT, et al. Economic appraisal of Ontario's Universal Influenza Immunization Program: a cost-utility analysis. PLoS Med. 2010;7(4):e1000256.
26. Canadian Paediatric Society. Influenza vaccine recommendations for children and youth for the 2008-2009 season. Paediatr Child Health. 2008;13(8):688-691.
27. Canadian Institute for Health Information (CIHI) [database on the Internet]. Available at: http://www.cihi.ca/CIHI-ext-portal/internet/EN/Home/home/cihi000001.
28. Ontario Health Insurance (OHIP) Schedule of Benefits and Fees. [database on the internet]. Available at: http://www.health.gov.on.ca/english/providers/program/ohip/sob/facility/ihf_mn.html.
29. Ontario Case Costing Initiative. [Webpage on the Internet]. Available at: http://www.occp.com/mainPage.htm. Accessed August 13, 2012.
30. Statistic Canada: [Database on the Internet]. Earnings, average hourly for hourly paid employees by industry. Available at: http://www41.statcan.gc.ca/2009/2621/tbl/cybac2621_2009_000_t10-eng.htm.
31. Hayden FG, Belshe RB, Clover RD, Hay AJ, Oakes MG, Soo W. Emergence and apparent transmission of rimantadine-resistant influenza A virus in families. N Engl J Med. 1989;321(25):1696-1702.
32. Briggs A, Claxton K, Sculpher M. Decision Modelling for Health Economic Evaluation. New York, NY: Oxford University Press; 2006.
33. Loeb M, Russell ML, Moss L, et al. Effect of influenza vaccination of children on infection rates in Hutterite communities: a randomized trial. JAMA. 2010;303(10):943-950.
34. Taddio A, Ipp M, Thivakaran S, et al. Survey of the prevalence of immunization non-compliance due to needle fears in children and adults. Vaccine. 2012;30(32):4807-4812.
35. Hull HF, O'Connor H. Optimizing protection against influenza in children eligible for the vaccine for children program. Pediatr Infect Dis J. 2010;29(10):910-914.
36. Block SL, Toback SL, Yi T, Ambrose CS. Efficacy of a single dose of live attenuated influenza vaccine in previously unvaccinated children: a post hoc analysis of three studies of children aged 2 to 6 years. Clin Ther. 2009;31(10):2140-2147.
37. Ambrose CS, Yi T, Walker RE, Connor EM. Duration of protection provided by live attenuated influenza vaccine in children. Pediatr Infect Dis J. 2008;27(8):744-748.
38. Fleming DM, Crovari P, Wahn U, et al; CAIV-T Asthma Study Group. Comparison of the efficacy and safety of live attenuated cold-adapted influenza vaccine, trivalent, with trivalent inactivated influenza virus vaccine in children and adolescents with asthma. Pediatr Infect Dis J. 2006;25(10):860-869.
39. Ashkenazi S, Vertruyen A, Aristegui J, et al; CAIV-T Study Group. Superior relative efficacy of live attenuated influenza vaccine compared with inactivated influenza vaccine in young children with recurrent respiratory tract infections. Pediatr Infect Dis J. 2006;25(10): 870-879.